Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma

Bioorg Med Chem Lett. 2004 Jul 16;14(14):3775-9. doi: 10.1016/j.bmcl.2004.04.099.

Abstract

Structure-activity relationships (SAR) of fused 1,2,4-triazolo[1,5-c ]pyrimidine were performed. Various substituents were introduced into the heterocyclic ring to improve the potency of adenosine A(3) receptor binding affinity and A(3)-selectivity against other subtypes. Potent and selective A(3) receptor antagonists were identified and were evaluated in a monkey model of intraocular pressure by eye-drop administration. As a result, compound 1c (OT-7999) was found to significantly decrease intraocular pressure in the animal model.

MeSH terms

  • Adenosine A3 Receptor Antagonists
  • Animals
  • Binding Sites
  • Disease Models, Animal
  • Drug Design
  • Glaucoma / drug therapy*
  • Haplorhini
  • Ligands
  • Pyrimidines / chemical synthesis*
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use
  • Receptor, Adenosine A3 / metabolism*
  • Structure-Activity Relationship
  • Time Factors
  • Triazoles / chemical synthesis*
  • Triazoles / pharmacology
  • Triazoles / therapeutic use

Substances

  • Adenosine A3 Receptor Antagonists
  • Ligands
  • Pyrimidines
  • Receptor, Adenosine A3
  • Triazoles